BACKGROUND: Sensitivity to pegvisomant therapy is highly variable in patients with acromegaly but determinants of this variability are still unknown. Lack of exon 3 (d3-) of the growth hormone (GH) receptor (GHR) has been associated with increased biological activity of GH. OBJECTIVE: To assess whether the presence of d3-GHR haplotype may have a role in predicting dose regimen and response to pegvisomant in acromegaly. DESIGN: Case series. Setting Institutional referral center at a tertiary care hospital. Patients Nineteen acromegalic patients with active disease after unsuccessful neurosurgery and somatostatin analog therapy. MEASUREMENTS: Before and 1, 3, 6 and 12 months after treatment with pegvisomant, IGF-I; GH receptor genotype, determined from peripheral blood by polymerase chain reaction. All patients started treatment with pegvisomant at 10 mg/daily and then increased the dose, according to a fixed schedule, during a 12-month follow-up until normalization of IGF-I levels. RESULTS: d3-GHR patients required a significant lower dose of pegvisomant and shorter treatment time to normalize IGF-I. CONCLUSION: The GHR genotype could be useful in predicting dose and individual response to pegvisomant in acromegaly.
BACKGROUND: Sensitivity to pegvisomant therapy is highly variable in patients with acromegaly but determinants of this variability are still unknown. Lack of exon 3 (d3-) of the growth hormone (GH) receptor (GHR) has been associated with increased biological activity of GH. OBJECTIVE: To assess whether the presence of d3-GHR haplotype may have a role in predicting dose regimen and response to pegvisomant in acromegaly. DESIGN: Case series. Setting Institutional referral center at a tertiary care hospital. Patients Nineteen acromegalicpatients with active disease after unsuccessful neurosurgery and somatostatin analog therapy. MEASUREMENTS: Before and 1, 3, 6 and 12 months after treatment with pegvisomant, IGF-I; GH receptor genotype, determined from peripheral blood by polymerase chain reaction. All patients started treatment with pegvisomant at 10 mg/daily and then increased the dose, according to a fixed schedule, during a 12-month follow-up until normalization of IGF-I levels. RESULTS: d3-GHRpatients required a significant lower dose of pegvisomant and shorter treatment time to normalize IGF-I. CONCLUSION: The GHR genotype could be useful in predicting dose and individual response to pegvisomant in acromegaly.
Authors: P J Godowski; D W Leung; L R Meacham; J P Galgani; R Hellmiss; R Keret; P S Rotwein; J S Parks; Z Laron; W I Wood Journal: Proc Natl Acad Sci U S A Date: 1989-10 Impact factor: 11.205
Authors: Pietro Maffei; Chiara Martini; Claudio Pagano; Nicola Sicolo; Francesco Corbetti Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina Journal: Eur J Endocrinol Date: 2005-12 Impact factor: 6.664
Authors: Alexander A L Jorge; Frederico G Marchisotti; Luciana R Montenegro; Luciani R Carvalho; Berenice B Mendonca; Ivo J P Arnhold Journal: J Clin Endocrinol Metab Date: 2005-11-15 Impact factor: 5.958
Authors: A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner Journal: Lancet Date: 2001-11-24 Impact factor: 79.321
Authors: Rebecca A Pelekanos; Varda S Sardesai; Marloes Dekker Nitert; Leonie K Callaway; Nicholas M Fisk; Penny L Jeffery Journal: Endocrine Date: 2015-06-12 Impact factor: 3.633
Authors: S Chiloiro; M Mormando; A Bianchi; A Giampietro; D Milardi; C Bima; G Grande; A M Formenti; G Mazziotti; A Pontecorvi; A Giustina; L De Marinis Journal: Endocrine Date: 2017-08-23 Impact factor: 3.633
Authors: Raquel S Jallad; Ericka B Trarbach; Felipe H Duarte; Alexander A L Jorge; Marcello D Bronstein Journal: Pituitary Date: 2015-10 Impact factor: 4.107
Authors: S Cannavo; F Bogazzi; A Colao; L De Marinis; P Maffei; R Gomez; E Graziano; M Monterubbianesi; S Grottoli Journal: J Endocrinol Invest Date: 2015-04-28 Impact factor: 4.256
Authors: Sanne E Franck; Linda Broer; Aart Jan van der Lely; Peter Kamenicky; Ignacio Bernabéu; Elena Malchiodi; Patric J D Delhanty; Fernando Rivadeneira; Sebastian J C M M Neggers Journal: Neuroendocrinology Date: 2016-08-12 Impact factor: 4.914